Full-Time

Vice President

Regulatory Affairs

Confirmed live in the last 24 hours

Tango Therapeutics

Tango Therapeutics

51-200 employees

Develops targeted cancer therapies using synthetic lethality

Biotechnology
Healthcare

Expert

Boston, MA, USA

Category
Risk & Compliance
Legal & Compliance

You match the following Tango Therapeutics's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor’s degree in life sciences, biochemistry, chemistry, biology or related pharmaceutical fields including biochemical engineering; advanced degree is desirable
  • Minimum 15 years of relevant biopharmaceutical industry experience, with at least 10 years' experience in Regulatory Affairs and deep experience in oncology; precision medicine given preference
  • Experience interacting with regulatory health authorities and experience with submitting CTA/IND and BLA/MAA filings, ideally in an area related to oncology
  • Familiarity with Chemistry, Manufacturing, and Control (CMC), Pharmacovigilance and Quality, related matters, and their intersection with Regulatory Affairs
  • Strong knowledge of drug and small molecule development regulations and guidelines including ICH, FDA, and EMA
  • Excellent written and verbal communication skills, strong technical knowledge, including regulatory writing
  • Strong leadership qualities including strategic thinking, innovation, mentoring, collaboration, etc
  • Solid working knowledge of drug development process and regulatory requirements in US and EU, Japan, Canada, and ROW a plus
  • Detail oriented; science-based reasoning skills
  • Ability to work in a fast-paced, start-up environment
  • Ability to work effectively in a collaborative team-oriented environment
  • Independently motivated and results oriented
Responsibilities
  • Provide global regulatory leadership to support development of multiple, innovative therapies for oncology
  • Maintain, manage, and develop a high performing regulatory team
  • Partner with key team members to develop strategies to advance our molecules from IND through pivotal studies and registration, leveraging a deep understanding of the landscape of precision oncology
  • Drive the planning and implementation of meetings with regulatory authorities and effectively represent Tango with regulatory interactions
  • Understand and interpret complex scientific issues for assigned projects as they relate to regulatory requirements and strategy for assigned projects, and provide knowledge and expertise to guide the team in appropriate regulatory strategy
  • Proactively identify regulatory issues; offer creative solutions and strategies, including risk mitigation
  • Manage and implement planning, authoring, and submission of high-quality briefing documents and clinical trial applications in the US, EU, Japan, and ROW
  • Accountable for all submissions and approvals for assigned project(s)
  • Direct point of contact with health authorities, lead and manage FDA/global health authority interactions/meetings for project responsibilities; prepare and submit responses to queries
  • Drive adherence to global regulatory guidelines relevant for the development of oncology products; author, review, and approve, as necessary, internal documentation to ensure conformance with regulations and existing regulatory approvals
  • Partner and work closely with Nonclinical, CMC, Quality, and Clinical to ensure achievement of submission deadlines, and obtain timely approvals of clinical trial applications
  • Monitor global regulatory guidelines and anticipate trends that may impact the regulatory environment to strengthen product development plan(s) and adopt regulatory strategies in a timely manner
  • Identify and implement processes, procedures, and systems appropriate for company size and stage
  • Provide Regulatory assessment to due diligence teams in terms of risks, requirements, and opportunities associated with collaborations
  • Additional duties and responsibilities as required
Desired Qualifications
  • Advanced degree is desirable

Tango Therapeutics develops targeted cancer treatments using the principle of synthetic lethality, which allows them to design drugs that kill cancer cells while leaving healthy cells unharmed. Their approach focuses on the interaction between genes, where the loss of both genes leads to cell death, but the loss of just one does not. This method enables them to create more effective therapies for cancer patients. Tango operates in the oncology market, primarily serving healthcare providers and pharmaceutical companies. They collaborate with larger pharmaceutical firms, like Gilead Sciences, to co-develop new therapies, which helps them secure funding and speed up the development process. Their goal is to bring next-generation targeted immunotherapies to market, supported by a strong team and strategic partnerships.

Company Size

51-200

Company Stage

IPO

Total Funding

$341.4M

Headquarters

Cambridge, Massachusetts

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing interest in synthetic lethality enhances Tango's innovative approach in oncology.
  • Recent $80 million financing strengthens Tango's financial position for future developments.
  • FDA clearance for TNG348 and TNG462 boosts Tango's clinical trial advancements.

What critics are saying

  • Discontinuation of TNG348 due to liver toxicity may affect investor confidence.
  • Reliance on partnerships for financial support poses risks if partnerships change.
  • Intensifying competition in precision oncology could impact Tango's market share.

What makes Tango Therapeutics unique

  • Tango leverages synthetic lethality to target cancer cells while sparing healthy ones.
  • Their focus includes counteracting tumor suppressor gene loss and immune evasion.
  • Strategic collaborations with pharma companies accelerate development and commercialization of therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

2%

2 year growth

8%
Business Wire
May 23rd, 2024
Tango Therapeutics Announces Discontinuation Of Tng348 Program

BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that it will discontinue development of its TNG348 program. “Patient safety is always our first priority and based on emerging data from the TNG348 dose escalation study, we have made the decision to discontinue further development of this molecule due to liver toxicity experienced by patients in the trial. While disappointing, we believe this is the right decision given the data at hand,” said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics. “We will focus resources and capital on our existing portfolio, particularly our PRMT5 program. We remain committed to and confident in our ability to deliver a comprehensive clinical update on TNG908 and TNG462 in the second half of this year.”

BioSpace
Mar 18th, 2024
Tango Therapeutics Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Business Highlights

BOSTON--(BUSINESS WIRE)-- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided business highlights.“In 2023, we made meaningful progress developing precision oncology treatments and now have four ongoing phase 1/2 clinical trials. These treatments have the potential to reach people with a wide range of cancers, including those with MTAP-deleted solid tumors, STK11 loss-of-function mutations, BRCA 1/2 mutations and other DNA damage repair defects. To support the advancement of our broad clinical portfolio, we expanded our management team, adding members with expertise in regulatory affairs and clinical development,” said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics. “We are off to a strong start in 2024, marked by dosing the first patient in the phase 1/2 clinical trial for TNG348, receiving Orphan Drug Designation from the U.S. FDA for TNG462 and strengthening our cash position

Business Wire
Mar 6th, 2024
Tango Therapeutics To Participate In Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the following upcoming investor conferences in March.Leerink Partners 2024 Global Biopharma ConferenceDate: Tuesday, March 12, 2024Time: 3:00 PM ETLocation: Miami, FLBarclays 26th Annual Global Healthcare ConferenceDate: Wednesday, March 13, 2024Time: 9:30 AM ETLocation: Miami, FLA live webcast of the presentations will be available under the "Events & Presentations" tab on the “Investors” page on the Company's website on the day of the event. A replay of the webcasts will be archived on the Company's website for 90 days following the presentation.About Tango TherapeuticsTango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. For more information, please visit www.tangotx.com

BioSpace
Sep 18th, 2023
Tango Therapeutics To Highlight Preclinical Data On Precision Oncology Pipeline At Aacr-Nci-Eortc International Conference On Molecular Targets And Cancer Therapeutics

BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been selected for poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place from October 11-15, 2023 in Boston, Massachusetts.Abstracts accepted for poster presentationTitle: MTA-cooperative PRMT5 inhibitors selectively modulate RNA splicing in MTAP-deleted cancer cells across histologies. Poster #: B018. Presenter: Matthew R. Tonini, Senior Scientist, Tango Therapeutics

Cision
Sep 11th, 2023
Medivir´S Partner Tango Therapeutics Received Fda Clearance To Start The Tng348 Phase 1/2 Clinical Study

Medivir´s Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study. .